Piotr Lazowski, MD
Nephrology · Plymouth, MANPI 1386691012
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $611 and has fallen 93.9% since, to $37 in 2025.
Across 47 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$129
- Novo Nordisk$120
- AstraZeneca$87
- Novartis$80
- Otsuka America Pharmaceutical, Inc.$57
- Johnson & Johnson$48
- plus $323 from 15 others
Across 418 payments — averaging $1265.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$448K
- Astrazeneca AB$79K
- AstraZeneca$2K
What the payments were for
- Food & beverage$82097%
- Education$253%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 5 | $129 |
| Novo Nordisk | 7 | $120 |
| AstraZeneca | 4 | $87 |
| Novartis | 5 | $80 |
| Otsuka America Pharmaceutical, Inc. | 2 | $57 |
| Johnson & Johnson | 2 | $48 |
| Bayer | 2 | $43 |
| Merck | 2 | $33 |
| Fresenius USA Marketing, Inc. | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $30 |
| Akebia Therapeutics Inc | 2 | $29 |
| Shire North American Group Inc | 1 | $25 |
| Vifor Pharma, Inc. | 1 | $20 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| OPKO Pharmaceuticals, LLC | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Strongbridge US Inc. | 1 | $13 |
| Sanofi | 1 | $12 |
| Travere Therapeutics, Inc. | 3 | $3 |
How this compares
$845 in reported general payments places this provider in the 60th percentile of 339 nephrology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 332 | $342,770 |
| VelphoroSucroferric Oxyhydroxide | 43 | $167,795 |
| EliquisApixaban | 425 | $160,160 |
| JardianceEmpagliflozin | 130 | $124,951 |
| KerendiaFinerenone | 99 | $122,682 |
| XifaxanRifaximin | 89 | $99,670 |
| IngrezzaValbenazine Tosylate | 11 | $73,389 |
| OzempicSemaglutide | 42 | $56,905 |
| JanuviaSitagliptin Phosphate | 120 | $36,822 |
| LokelmaSodium Zirconium Cyclosilicate | 34 | $33,562 |
| TrulicityDulaglutide | 32 | $32,961 |
| Cinacalcet Hcl | 49 | $30,094 |
| XareltoRivaroxaban | 85 | $29,866 |
| ProcritEpoetin Alfa | 29 | $29,750 |
| RetacritEpoetin Alfa-Epbx | 22 | $25,867 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $87 | $376,333366 claims |
| Fresenius USA Marketing, Inc.Velphoro | $30 | $167,79543 claims |
| BayerKerendia | $43 | $122,68299 claims |
| Johnson & JohnsonXarelto, Procrit | $48 | $59,616114 claims |
| Novo NordiskOzempic | $120 | $56,90542 claims |
| MerckJanuvia | $33 | $36,822120 claims |
| Akebia Therapeutics IncAuryxia | $29 | $24,10814 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $57 | $7,16819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 339 nephrology providers in Massachusetts.
Other nephrology in Plymouth
- David FriedmanBoston$19.8M
- Martin PollakBoston$19.8M
- Dennis AusielloBoston$4.6M
- Ajay SinghBoston$916K
- Michael GermainSpringfield$443K
- Rekha AbichandaniCambridge$442K
- Leslie FangBoston$388K
- Nicolaos AthienitesBrockton$294K
- Jean FrancisBoston$244K
- Joshua HundertDorchester$229K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.